98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00428-024-03991-6 | DOI Listing |
J Palliat Med
September 2025
ATLANTES Global Observatory of Palliative Care, Instituto Cultura y Sociedad, Universidad de Navarra, Navarra, Spain.
International research projects, such as Horizon 2020 (H2020) and ERASMUS+, generate numerous scientific and educational outcomes. However, these are often disseminated in fragmented formats, limiting long-term access and impact. Language barriers further complicate the dissemination in professional communities that do not speak English.
View Article and Find Full Text PDFJ Rehabil Med Clin Commun
September 2025
Department of Medicine, Division of Endocrinology, Western University, London, Canada.
Objective: People who have experienced stroke are at a high risk for falls, fractures, and osteoporosis. Bone health post-stroke is often overlooked. The goal of this study was to understand current practice perspectives and barriers to bone health care post-stroke among physiatrists.
View Article and Find Full Text PDFMed Educ
September 2025
University of Miami Gordon Center for Simulation and Innovation in Medical Education, Miami, Florida, USA.
Introduction: Speaking up about medical errors is a critical behaviour for medical students, as it plays a vital role in enhancing patient safety. Few studies have explored the drivers and barriers affecting their willingness to speak up in clinical training, particularly within hierarchical Asian cultures. The purpose of this study was to explore drivers and barriers shaping medical students' speaking up behaviours about medical errors to inform education, mentorship and patient safety practices.
View Article and Find Full Text PDFExp Neurobiol
August 2025
Institute of Medical Science, Ajou University School of Medicine, Suwon 16499, Korea.
Neural tumors represent diverse malignancies with distinct molecular profiles and present particular challenges due to the blood-brain barrier, heterogeneous molecular etiology including epigenetic dysregulation, and the affected organ's critical nature. KCC-07, a selective and blood-brain barrier penetrable MBD2 (methyl CpG binding domain protein 2) inhibitor, can suppress tumor development by inducing p53 signaling, proven only in medulloblastoma. Here we demonstrate KCC-07 treatment's application to other neural tumors.
View Article and Find Full Text PDFJTCVS Open
August 2025
Department of Surgery, Thoracic Service, Memorial Sloan Kettering Cancer Center, New York, NY.